On December 15, 2021, Roche released the 2021 ash series data report meeting. December 11-14, 2021, Roche published a series of clinical research data on innovative therapies for different blood diseases at the American Society of Hematology (ash) annual meeting in 2021. Roche published more than 100 abstracts and made more than 30 oral reports at this meeting. On December 15, Roche released a public speech to summarize the data of this ash annual meeting. Among them, from Polivy (anti-cd79badc), mosunetuzumab (cd20xcd3 double antibody), hemliba (factor IX agonist), etc. are expected to redefine the standard treatment of a variety of blood diseases.
Roche's development vision in 2030: improve curative effect and reduce the treatment burden of patients. The five core varieties of hematoma include: polyvy (anti-cd79b ADC); Mosunetuzumab (cd20xcd31:1 double antibody); Glofitimab (cd20xcd3 2:1 double antibody); Cevostamab (fcrh5xcd3 double antibody); Venclexta(Bcl-2)。 The core varieties of benign hematological diseases include: 1) hemlibra; 2) Spk-8011 (AAV delivery system); 3) crovalimab (C5 antibody).
Mosunetuzumab: 1) recurrent / refractory follicular lymphoma (R / R FL) reached the main clinical end point, Cr reached 60%, much higher than 14% of the historical control; it is the first CD3 double antibody with significant curative effect on FL, and may realize off the shelf; 2) the combination of pola in the treatment of R / rb-nhl has both efficacy and safety, and the phase 3 clinical trial of combined treatment regimen 2L + DLBCL has been opened.
Glofitamab: the total orr of phase I R / R MCL step-up doing test reached 81%, of which CR reached 67%; Has off the shelf potential.
Polivy: the median follow-up was 28.2 months, and the study reached the primary endpoint. Compared with the R-CHOP treatment group, The disease progression free survival (PFS) was significantly improved and clinically significant in the poly + r-chp treatment group. Compared with the R-CHOP group, the relative risk of disease progression, recurrence or death in the poly + r-chp treatment group was significantly reduced by 27%; the 2-year PFS rate was 76.7% vs.70.2%; the event free survival (EFS) was better (HR = 0.75) and the disease-free survival (DFS) was better (HR = 0.70), there was no difference in overall survival (OS) (HR = 0.94), and there was no significant difference in complete remission rate of PET-CT (78.0% vs 74.0%).
Risk warning: R & D fails or progress is lower than expected; Promotion of clinical research on the impact of covid-19 pneumonia epidemic situation
